IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation

We read with excitement the article titled "Life-threatening NLRC4-associated hyperinflammation successfully treated with Interleukin-18 inhibition" by Canna et al.1 We congratulate the authors for this outstanding diagnostic and therapeutic triumph. This article also represents translation from the bench of a unique protein, the IL-18 binding protein (IL-18BP),2 into a targeted therapy drug that saved the life of this child. IL-18BP was an unexpected discovery and we believe that a short description of its unique features3,4 is useful to scientists and essential to clinicians and therefore should have been included in the publication of Canna et al.

http://ift.tt/2pHonYI